WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Richard E. UihleinDirector2026-07-3131,825,235$3.00
$95.48MBuy
Richard E. UihleinDirector2026-07-312,550,932$4.05
$10.33MBuy
Khurram JamilChief2026-07-1416,250$5.13
$83.28kSell
Khurram JamilChief2026-07-1416,250$3.04
$49.40kBuy
Khurram JamilChief Medical Officer2026-06-2947,467$2.50
$118.67kBuy
Harold H. ShlevinDirector2026-06-2922,268$1.23
$27.39kBuy
Khurram JamilChief Medical Officer2026-06-2947,467$5.04
$239.23kSell
Harold H. ShlevinDirector2026-06-2922,268$5.04
$112.23kSell
Khurram JamilChief Medical Officer2026-06-262,037$5.00
$10.19kSell
Khurram JamilChief Medical Officer2026-06-262,037$2.20
$4.48kBuy

1 of 14

GALT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Richard E. Uihlein54.64%55,101,939$202.22MInsider
10x Fund LP22.08%22,271,880$81.74MInsider
James C. Czirr20.84%21,015,907$77.13MInsider
Rod D. Martin11.96%12,057,197$44.25MInsider
David Platt8.35%8,418,743$30.90MInsider
Joel Lewis0.83%836,592$3.07MInsider
Kevin D. Freeman0.23%229,332$841.65kInsider
Arthur Greenberg0.11%109,445$401.66kInsider
Peter G. Traber0.11%107,333$393.91kInsider
Steven Prelack0.11%107,189$393.38kInsider

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT0.01%99.99%Net BuyingNet Buying
PALI0.10%6.97%Net SellingNet Selling
IPSC0.09%23.38%Net SellingNet Selling
DMAC0.02%69.10%Net Buying
STRO0.10%92.06%Net Buying
View Top Biotech Stocks

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 0.02% institutional shareholders, 119.72% Galectin Therapeutics insiders, and 0.00% retail investors. Richard E. Uihlein is the largest individual Galectin Therapeutics shareholder, owning 55.10M shares representing 54.64% of the company. Richard E. Uihlein's Galectin Therapeutics shares are currently valued at $196.71M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.